EUVIMEDEUVIMED entdecken
Open Access

Valosin‐containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group

Fieke W Hoff iD, Yihua Qiu, Brandon D Brown, Robert B Gerbing, Amanda R Leonti, Rhonda E Ries, Alan S Gamis, Richard Aplenc, Edward Anders Kolb, Todd A Alonzo, Soheil Meshinchi, Gaye N Jenkins und 2 weitere

PROTEOMICS – Clinical Applications · 2023

DOI: 10.1002/prca.202200109 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PROTEOMICS – Clinical Applications, 2023. Verfasst von Fieke W Hoff und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Cell Cycle Proteins, Endoplasmic Reticulum Chaperone BiP. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, St. Baldrick's Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The endoplasmic reticulum (ER) is the major site of protein synthesis and folding in the cell. ER‐associated degradation (ERAD) and unfolded protein response (UPR) are the main mechanisms of ER‐mediated cell stress adaptation. Targeting the cell stress response is a promising therapeutic approach in acute myeloid leukemia (AML). Experimental Design Protein expression levels of valosin‐containing protein (VCP), a chief element of ERAD, were measured in peripheral blood samples from in 483 pediatric AML patients using reverse phase protein array methodology. Patients participated in the Children's Oncology Group AAML1031 phase 3 clinical trial that randomized patients to standard chemotherapy (cytarabine (Ara‐C), daunorubicin, and etoposide [ADE]) versus ADE plus bortezomib (ADE+BTZ).

Results

Low‐VCP expression was significantly associated with favorable 5‐year overall survival (OS) rate compared to middle‐high‐VCP expression (81% versus 63%, p < 0.001), independent of additional bortezomib treatment. Multivariable Cox regression analysis identified VCP as independent predictor of clinical outcome. UPR proteins IRE1 and GRP78 had significant negative correlation with VCP. Five‐year OS in patients characterized by low‐VCP, moderately high‐IRE1 and high‐GRP78 improved after treatment with ADE+BTZ versus ADE (66% versus 88%, p = 0.026). Conclusion and Clinical Relevance Our findings suggest the potential of the protein VCP as biomarker in prognostication prediction in pediatric AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell Cycle ProteinsEndoplasmic Reticulum Chaperone BiPChildHumansBortezomibProtein Serine-Threonine KinasesUnfolded Protein ResponseValosin Containing ProteinEndoribonucleases

Stichwörter der Autor:innen

AMLERADGRP78IRE1RPPAUPRVCPleukemiapediatric

Substanzen

BortezomibCell Cycle ProteinsEndoplasmic Reticulum Chaperone BiPProtein Serine-Threonine KinasesValosin Containing ProteinVCP protein, humanHSPA5 protein, humanERN1 protein, humanEndoribonucleases

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • COG Statistics and Data Center, Monrovia, California, USA.
  • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Department of Hematology-Oncology, Children's Mercy Hospitals and Clinics, Kansas City, Missouri, USA.

ORCID-Profile: Fieke W Hoff

Förderung

  • NCI NIH HHS
  • St. Baldrick's Foundation

Zitieren

APA

Hoff, F. W., Qiu, Y., Brown, B. D., Gerbing, R. B., Leonti, A. R., Ries, R. E., Gamis, A. S., Aplenc, R., Kolb, E. A., Alonzo, T. A., Meshinchi, S., Jenkins, G. N., Horton, T. M., & Kornblau, S. M. (2023). Valosin‐containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group. PROTEOMICS – Clinical Applications. https://doi.org/10.1002/prca.202200109

Vancouver

Hoff FW, Qiu Y, Brown BD, Gerbing RB, Leonti AR, Ries RE, et al. Valosin‐containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group. PROTEOMICS – Clinical Applications. 2023. doi:10.1002/prca.202200109

BibTeX
@article{Hoff2023,
  author = {Hoff, Fieke W and Qiu, Yihua and Brown, Brandon D and Gerbing, Robert B and Leonti, Amanda R and Ries, Rhonda E and Gamis, Alan S and Aplenc, Richard and Kolb, Edward Anders and Alonzo, Todd A and Meshinchi, Soheil and Jenkins, Gaye N and Horton, Terzah M and Kornblau, Steven M},
  title = {Valosin‐containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group},
  journal = {PROTEOMICS – Clinical Applications},
  year = {2023},
  doi = {10.1002/prca.202200109}
}
Kostenlos starten →